Clinical trial registry record

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 12, 2014.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00637377
Last registry update
December 12, 2014
Status
Completed
Phase
Phase 3
Sponsor
Bayer
Enrollment
1240
Countries
Argentina, Australia, Austria, Belgium, Brazil, Colombia, Czechia, France, Germany, Hungary, India, Israel, Italy, Japan, Latvia, Mexico, Netherlands, Poland, Portugal, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
Evidence population
Human clinical study registration
Participants
1240
Population
ALL · 50 Years
Duration
2008-04-01 to 2011-08-01
Intervention
Ranibizumab; Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Comparator
Ranibizumab 0.5mg Q4
Outcomes measured
Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) — At week 52; Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF —…; Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week…; Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at W…; Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF — Baseline and at week 52
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON